Trump slaps 100% tariff on generic drugs in US manufacturing push

Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

17 September 2026 Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal.

Regulation & Industry

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

14 September 2026 Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.

Regulation & Industry

Built to be bought? What makes companies acquisition-ready

11 September 2026 For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

More features

Benesch adds former McDermott IP practice head

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

Trump slaps 100% tariff on generic drugs in US manufacturing push

More on this story

Editor's picks

Editor's picks

More features